Pharma Mar, S.A. (BME:PHM)

Market Cap	1.43B
Revenue (ttm)	175.75M
Net Income (ttm)	19.88M
Shares Out	17.57M
EPS (ttm)	n/a
PE Ratio	71.98
Forward PE	28.61
Dividend	0.80 (1.01%)
Ex-Dividend Date	Jun 25, 2025

Volume	65,651
Average Volume	79,898
Open	81.40
Previous Close	79.10
Day's Range	80.35 - 82.70
52-Week Range	31.82 - 105.80
Beta	-0.11
RSI	47.15
Earnings Date	Jul 25, 2025

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata for the treatment of soft tissue sarcoma and recurrent ovarian cancer; Aplidin i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 500
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: PHM

Financial Performance

In 2024, Pharma Mar's revenue was 174.86 million, an increase of 10.56% compared to the previous year's 158.15 million. Earnings were 26.13 million, an increase of 2197.71%.